LXR agonists have the potential to inhibit tumor proliferation and survival, as well as to elicit significant antitumor immunity effects.287 A recent study reported that the LXRβ agonists, GW3965 and RGX-104, reduced the MDSCs levels in several mouse tumor models.288 Mechanistically, LXR agonism upregulated the transcriptional target apolipoprotein E (ApoE), which bound to low-density lipoprotein receptor-related protein 8 (LRP8) on MDSCs to reduce MDSCs survival. Here, APOE is linked to neoplasm.